Renoprotective effects of atorvastatin compared with pravastatin on progression of early diabetic nephropathy

フォーマット:

論文

責任表示:

Takazakura, Akiko ; Sakurai, Masaru ; Bando, Yukihiro ; Misu, Hirofumi ; Takeshita, Yumie ; Kita, Yuki ; Shimizu, Akiko ; Hayakawa, Tetsuo ; Kato, Ken-ichiro ; Kaneko, Shuichi ; Takamura, Toshinari

言語:

英語

出版情報:

Blackwell Publishing, 2015-05-01

著者名:

Takazakura, Akiko

Sakurai, Masaru

Bando, Yukihiro

Misu, Hirofumi

Takeshita, Yumie

Kita, Yuki

Shimizu, Akiko

Hayakawa, Tetsuo

Kato, Ken-ichiro

Kaneko, Shuichi

Takamura, Toshinari

続きを見る

掲載情報:

Journal of Diabetes Investigation

ISSN:

2040-1116      

巻:

6

通号:

3

開始ページ:

346

終了ページ:

353

バージョン:

publisher

概要:

Introduction: Several studies have shown that statins suppress the progression of diabetic nephropathy. However, few reports have directly compared the renoprotective effects between potent and conventional statins. Materials and Methods: Patients with diabetic nephropathy, selected as those with a serum creatinine level of 0.9-1.5 mg/dL and simultaneously having either microalbuminuria or positive proteinuria, were randomly assigned to one of three … groups: a conventional diet therapy group, a group given 10 mg of pravastatin and a group given 10 mg of atorvastatin. Renal function was evaluated before and after a 12-month period of therapy. Results: The atorvastatin group had a significant decrease in low-density lipoprotein cholesterol at 3 months and thereafter compared with the other groups. The urinary albumin-to-creatinine ratio significantly decreased in the atorvastatin group; the degree of this decrease was significantly greater than that in the diet therapy group. The kidney function estimated with cystatin C (CysC) and the estimated glomerular filtration rate calculated from CysC were significantly preserved in the atorvastatin group compared with the pravastatin group. In a multivariate regression analysis, the use of atorvastatin was the only explanatory variable for the changes in CysC; this was independent of changes in low-density lipoprotein cholesterol. Conclusions: Atorvastatin is more effective than pravastatin for the prevention of increase in CysC, and this renoprotective effect was considered to a result of the pleiotropic effect of atorvastatin independent of its lipid-lowering effect. This study was registered with UMIN (no. UMIN 000001774). © 2014 The Authors. 続きを見る

URL:

http://hdl.handle.net/2297/45713